Bradley Radoff and Jumana Capital disclosed a 7.6% stake in Genesco Inc. (NYSE: GCO) through a Schedule 13D filing, marking the formation of an activist group with explicit board representation intent. The combined position values approximately $45 million at Friday's close of $29.87 per share, a 4.2% single-session gain on the disclosure. Radoff, operating through his investment vehicle, holds 5.1%; Jumana Capital controls 2.5%.

The 13D language is unambiguous. Both parties state they "may seek representation on the Board of Directors" and intend to engage management on "strategic alternatives to enhance shareholder value." The filing does not specify immediate proxy contest mechanics, but the coordination clause—designating Radoff as the group's representative for SEC communications—signals operational readiness. Genesco's board currently seats nine directors, seven of whom are independent. The company's staggered board structure requires a majority vote to amend, but two seats come up for election at the next annual meeting, typically scheduled for late June.

Genesco operates 1,425 retail locations under Journeys, Schuh, and Johnston & Murphy banners, generating $2.1 billion in trailing twelve-month revenue. The stock trades at 0.28x sales and 6.8x forward earnings, a 32% discount to the S&P Retail Select Sector average. Free cash flow conversion improved to 8.1% in fiscal 2024 from 5.3% the prior year, but same-store sales declined 2.7% in the most recent quarter. The company carries $847 million in total debt against $104 million in cash, leaving net leverage at 3.6x EBITDA. Management suspended share repurchases in Q3 to preserve liquidity.

Radoff's prior campaigns include a board seat at Perry Ellis International in 2019 and a proxy fight at Destination XL Group in 2021, both resulting in operational overhauls and eventual sale processes. Jumana Capital, a smaller long-only vehicle with estimated AUM below $150 million, has not publicly disclosed prior activist positions. The pairing suggests Radoff sources financial backing outside his core vehicle, a structure used when target market caps exceed single-manager capacity.

The filing does not propose specific governance changes or asset sales, but the timing aligns with Genesco's fiscal year-end reporting cycle. The company reports Q4 earnings on March 13, which will include updated fiscal 2025 guidance and any commentary on strategic reviews. Board nomination deadlines typically fall 120 days before the annual meeting, placing the cutoff in late February if the meeting holds its usual June slot. Radoff and Jumana have filed no proxy materials as of this writing, but the 13D's "continuous dialogue" language suggests private engagement is already underway.

The market assigned a $24 million premium to Genesco's equity value on the news, a muted reaction relative to the 11-14% average first-day pop in 13D filings at sub-$1 billion retailers over the past eighteen months. That spread implies either skepticism about execution risk or early positioning by arbs anticipating a drawn-out engagement. Genesco's next substantive disclosure obligation is the 8-K following any board composition agreement or the proxy filing if negotiations stall.